Tempus AI, Inc.
StreetZero Signal 68
About Tempus AI, Inc.
Tempus AI, Inc. (legal name Tempus Labs, Inc.) is a biotechnology research company founded in 2015 and headquartered in Chicago, IL. It operates a B2B SaaS platform that uses AI to process and analyze medical data, helping doctors improve patient treatment through precision medicine and diagnostics. The company went public on Nasdaq under ticker TEM in June 2024 after raising $410.7 million in its IPO at $37 per share.
LATEST FUNDINGRule 144
$15.9M
Announced 2026-11-19
TOTAL RAISED$2.75B
IN THE NEWS
EMPLOYEES3800
FOUNDED2015
HQChicago, IL, United States
Industry
Public Equity (NASDAQ)
Tags
B2BSaaSBiotechnologyAIHealthcare
Investors
Key highlights
- Completed Nasdaq IPO in June 2024 raising $410.7M at $37 per share with a $6B+ valuation.
- Uses AI for medical data analysis and diagnostics in precision medicine.
- Backed by Google and major growth investors including NEA and T. Rowe Price.
- Maintains strategic collaborations with AstraZeneca, GSK, Merck and others.
- Public company with 3,800 employees and over 139k LinkedIn followers.
Ask StreetZero about Tempus AI, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account